Phthalic Anhydride Market Moved Up This Week (Nov 3-9, 2017)
Market Review: The Chinese phenol market continued the uptrend this week. Negotiation prices moved up. Up to December 7, the reference negotiation prices for phenol in East China were in the range of RMB 10,200-10,400/mt, up RMB 750/mt week on week. The average price was RMB 10,000/mt, up 6.72% week on week. The benzene prices fluctuated at high levels, but phenol market saw no pressure. Supply and demand were the major influencing factors. The supply was tight in the market, and holders controlled the sales. Phenol producers raised prices again to RMB 10,000/mt. The BPA market followed the uptrend. The profits were fine. Players were cautious and optimistic.
Forecast: The tight supply is the major reason for the firm phenol market. Some imported goods will arrive. But some phenolic ketone units in China will undergo maintenance in the future. Producers will see no sales pressure. It is predicted that the Chinese phenol market will inch up next week.
Looking for chemical products? Let suppliers reach out to you!
2026-07-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Recommend Reading
-
Early September Acetic Acid Market Remains Strong
-
Chinese Hydrofluoric Acid Market Shows a Steady and Slightly Strong Trend
-
Limited Positive Factors Drive Downward Trend in Shandong Butanol Prices in Early September
-
Oil Coke to Rise Sharply in 2025, Likely to Experience Relatively Strong Volatility in 2026
-
This Week's Epichlorohydrin Market Prices Remain Stable in China (1.12-1.16)
-
ExxonMobil Shuts Another Singapore Facility: The Global Petrochemical Shake-Up Leaves No Easy Winners
-
ECHEMI WPO and Pharmaceutical Division Showcase Dual Strengths at the 94th API China, Tackling Pharmaceutical Export Challenges with Precision
-
72 Hours at API China: Where China’s API Export Industry Is Heading Next
-
Dietary Supplement Listing Debate Puts Nutrition Ingredients Under a Brighter Spotlight
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition